Thomas Schluep

3.7k total citations
47 papers, 2.6k citations indexed

About

Thomas Schluep is a scholar working on Molecular Biology, Epidemiology and Biomaterials. According to data from OpenAlex, Thomas Schluep has authored 47 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 18 papers in Epidemiology and 10 papers in Biomaterials. Recurrent topics in Thomas Schluep's work include Hepatitis B Virus Studies (17 papers), RNA Interference and Gene Delivery (16 papers) and Nanoparticle-Based Drug Delivery (9 papers). Thomas Schluep is often cited by papers focused on Hepatitis B Virus Studies (17 papers), RNA Interference and Gene Delivery (16 papers) and Nanoparticle-Based Drug Delivery (9 papers). Thomas Schluep collaborates with scholars based in United States, Hong Kong and Australia. Thomas Schluep's co-authors include Mark E. Davis, Jungyeon Hwang, Bruce D. Given, Ching‐Lung Lai, Robert G. Gish, Stephen Locarnini, Jeremy D. Heidel, Johnson Y.N. Lau, David L. Lewis and Jianjun Cheng and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Thomas Schluep

47 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Schluep United States 24 1.2k 873 690 645 453 47 2.6k
Srikanta Dash United States 30 1.3k 1.0× 905 1.0× 698 1.0× 304 0.5× 252 0.6× 77 2.7k
Sonya A. MacParland Canada 16 672 0.6× 574 0.7× 671 1.0× 409 0.6× 495 1.1× 51 2.2k
K. Kawano Japan 31 1.4k 1.2× 117 0.1× 183 0.3× 1.2k 1.9× 573 1.3× 110 3.2k
Alfica Sehgal United States 21 1.9k 1.6× 261 0.3× 175 0.3× 153 0.2× 255 0.6× 37 2.6k
Ronald Bordens United States 16 605 0.5× 342 0.4× 372 0.5× 112 0.2× 69 0.2× 22 1.8k
Mary C. Graves United States 18 935 0.8× 294 0.3× 287 0.4× 96 0.1× 74 0.2× 33 2.2k
Wilson Poon Canada 11 1.1k 0.9× 121 0.1× 101 0.1× 1.3k 1.9× 1.3k 2.9× 21 2.8k
Scott Barros United States 14 1.8k 1.5× 74 0.1× 117 0.2× 372 0.6× 321 0.7× 20 2.4k
Wilson S. Meng United States 24 844 0.7× 147 0.2× 86 0.1× 334 0.5× 246 0.5× 61 1.8k

Countries citing papers authored by Thomas Schluep

Since Specialization
Citations

This map shows the geographic impact of Thomas Schluep's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Schluep with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Schluep more than expected).

Fields of papers citing papers by Thomas Schluep

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Schluep. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Schluep. The network helps show where Thomas Schluep may publish in the future.

Co-authorship network of co-authors of Thomas Schluep

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Schluep. A scholar is included among the top collaborators of Thomas Schluep based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Schluep. Thomas Schluep is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brugarolas, James, Kathryn E. Beckermann, Brian I. Rini, et al.. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 30(11). 2402–2411. 12 indexed citations
2.
Mak, Lung‐Yi, Christine I. Wooddell, Oliver Lenz, et al.. (2024). Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 74(3). 440–450. 17 indexed citations
3.
Strnad, Pavel, Mattias Mandorfer, Gourab Choudhury, et al.. (2022). Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency. New England Journal of Medicine. 387(6). 514–524. 65 indexed citations
4.
5.
Yuen, Man‐Fung, Danny Ka‐Ho Wong, Thomas Schluep, et al.. (2021). Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut. 71(4). 789–797. 37 indexed citations
6.
Locarnini, Stephen, Bruce D. Given, Thomas Schluep, et al.. (2019). First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA). Hepatology. 70(6). 7 indexed citations
7.
Wooddell, Christine I., Man‐Fung Yuen, Henry Lik‐Yuen Chan, et al.. (2017). RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine. 9(409). 342 indexed citations
8.
Schluep, Thomas, et al.. (2016). Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520. Hepatology International. 1 indexed citations
9.
Walsh, Renae, R. Hammond, Lilly Yuen, et al.. (2016). Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAI) Therapy Based on HBsAg Epitope Profile Analysis. Journal of Hepatology. 64(2). S602–S602. 3 indexed citations
10.
Gish, Robert G., Man‐Fung Yuen, Henry Lik‐Yuen Chan, et al.. (2015). Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Research. 121. 97–108. 113 indexed citations
11.
Gish, Robert G., Bruce D. Given, Ching‐Lung Lai, et al.. (2015). Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Research. 121. 47–58. 188 indexed citations
12.
Schluep, Thomas, et al.. (2011). CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development. Current Bioactive Compounds. 7(1). 8–14. 78 indexed citations
13.
Alizadeh, Darya, Leying Zhang, Jungyeon Hwang, Thomas Schluep, & Behnam Badie. (2009). Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine Nanotechnology Biology and Medicine. 6(2). 382–390. 81 indexed citations
14.
Schluep, Thomas, et al.. (2008). Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity. Clinical Cancer Research. 15(1). 181–189. 49 indexed citations
15.
Schluep, Thomas, et al.. (2005). Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemotherapy and Pharmacology. 57(5). 654–662. 118 indexed citations
16.
Machemer, Todd, Heidrun Engler, Van Tsai, et al.. (2005). Characterization of Hemodynamic Events Following Intravascular Infusion of Recombinant Adenovirus Reveals Possible Solutions for Mitigating Cardiovascular Responses. Molecular Therapy. 12(2). 254–263. 13 indexed citations
17.
Engler, Heidrun, Todd Machemer, Thomas Schluep, et al.. (2003). Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice. Molecular Therapy. 7(4). 558–564. 10 indexed citations
18.
Schluep, Thomas. (1998). Purification of plasmids by triplex affinity interaction. Nucleic Acids Research. 26(19). 4524–4528. 68 indexed citations
19.
Schluep, Thomas & Charles L. Cooney. (1998). Immobilization of oligonucleotides on a large pore support for plasmid purification by triplex affinity interaction. PubMed. 7(6). 317–326. 9 indexed citations
20.
Prazeres, D.M.F., Thomas Schluep, & Charles L. Cooney. (1998). Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography. Journal of Chromatography A. 806(1). 31–45. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Srikanta Dash Breakdown of academic impact, for papers by Sonya A. MacParland Breakdown of academic impact, for papers by K. Kawano Breakdown of academic impact, for papers by Alfica Sehgal Breakdown of academic impact, for papers by Ronald Bordens Breakdown of academic impact, for papers by Mary C. Graves Breakdown of academic impact, for papers by Wilson Poon Breakdown of academic impact, for papers by Scott Barros Breakdown of academic impact, for papers by Wilson S. Meng
Rankless by CCL
2026